How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?   

At Sylvester we have found that patients with GIST whose tumors progress in imatinib often harbor resistance mutations that may be detected by a blood test called “circulating tumor DNA”. There is growing evidence that patients with one type of mutation do much better with sunitinib whil...

This is an interesting and constantly evolving question. It is important to note that 80% of GIST have a mutation in KIT gene, with a further 10-12% having mutations in PDGFR gene. The remaining small fraction are referred to as wild type. It is important that note that wild-type GIST does not respo...